Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Expectations for Eli Lilly’s ramucirumab were dampened after it failed in a Phase III trial in breast cancer patients, but enthusiasm for the drug has been reignited now that it demonstrated a survival benefit in one of oncology’s riskiest areas – lung cancer.